Accessibility Menu
 
Protagonist Therapeutics logo

Protagonist Therapeutics

(NASDAQ) PTGX

Current Price$98.98
Market Cap$6.32B
Since IPO (2016)+746%
5 Year+242%
1 Year+116%
1 Month-6%

Protagonist Therapeutics Financials at a Glance

Market Cap

$6.32B

Revenue (TTM)

$46.02M

Net Income (TTM)

$130.15M

EPS (TTM)

$-2.04

P/E Ratio

-48.45

Dividend

$0.00

Beta (Volatility)

1.29 (Average)

Price

$98.98

Volume

25,931

Open

$99.55

Previous Close

$98.98

Daily Range

$97.26 - $100.64

52-Week Range

$41.28 - $107.84

PTGX: Motley Fool Moneyball Superscore

80

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Protagonist Therapeutics

Industry

Biotechnology

Employees

132

CEO

Dinesh V. Patel, PhD

Headquarters

Newark, CA 94560-1160, US

PTGX Financials

Key Financial Metrics (TTM)

Gross Margin

99%

Operating Margin

-3%

Net Income Margin

-3%

Return on Equity

-20%

Return on Capital

-25%

Return on Assets

-19%

Earnings Yield

-2.06%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.32B

Shares Outstanding

63.81M

Volume

25.93K

Avg. Volume

759.85K

Financials (TTM)

Gross Profit

$44.79M

Operating Income

$158.13M

EBITDA

$128.09M

Operating Cash Flow

$57.67M

Capital Expenditure

$1.59M

Free Cash Flow

$56.08M

Cash & ST Invst.

$567.36M

Total Debt

$10.32M

Protagonist Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$7.44M

-95.6%

Gross Profit

$7.06M

-95.9%

Gross Margin

94.94%

N/A

Market Cap

$6.32B

N/A

Market Cap/Employee

$50.93M

N/A

Employees

124

N/A

Net Income

$44.38M

-133.7%

EBITDA

$43.34M

-134.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$557.04M

+36.5%

Accounts Receivable

$4.50M

-97.3%

Inventory

$0.00

N/A

Long Term Debt

$8.04M

-22.4%

Short Term Debt

$2.28M

+347.6%

Return on Assets

-19.43%

N/A

Return on Invested Capital

-25.32%

N/A

Free Cash Flow

$35.53M

-20.5%

Operating Cash Flow

$36.98M

-26.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KYMRKymera Therapeutics, Inc.
$81.07-0.54%
ACLXArcellx, Inc.
$115.07+0.00%
ALKSAlkermes plc
$33.71+0.00%
IMVTImmunovant, Inc.
$27.14+0.72%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$12.91+0.04%
AMZNAmazon
$265.06+0.01%
SOFISoFi Technologies
$16.10+0.04%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.63+0.10%

Questions About PTGX

What is the current price of Protagonist Therapeutics?

Protagonist Therapeutics is trading at $98.98 per share.

What is the 52-week range for Protagonist Therapeutics?

Over the past 52 weeks, Protagonist Therapeutics has traded between $41.29 and $107.84.

How much debt does Protagonist Therapeutics have?

As of the most recent reporting period, Protagonist Therapeutics reported total debt of $10.32M.

How much cash does Protagonist Therapeutics have on hand?

Protagonist Therapeutics reported $128.39M in cash and cash equivalents in its most recent financial results.

What is Protagonist Therapeutics’s dividend yield?

Protagonist Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.